Association between anti-erythropoietin antibody levels and treatment response in hemodialysis patients with end-stage renal disease: A cross-sectional study from Iraq
Journal of Nephropharmacology · 09.11.2025 · 15 (1) · e12808
DOI: 10.34172/npj.2025.12808 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Journal of Nephropharmacology, online erschienen am 09.11.2025. Verfasst von Samer Imad Mohammed und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
The therapeutic efficacy of erythropoietin (EPO) may be diminished by the formation of anti-erythropoietin antibodies (AEAs), potentially resulting in therapy failure.
Objectives
This retrospective study included 84 hemodialysis patients with end-stage renal disease (ESRD) treated with recombinant EPO and aimed to evaluate the association between serum AEA and treatment response. Patients and Methods: This cross-sectional study included eighty-four Iraqi patients with ESRD who had been on recombinant human EPO for more than 6 months and had hemoglobin levels below 11 g/dL. Serum AEA levels were measured in all patients to evaluate their association with treatment response and to investigate correlations with demographic, clinical, and laboratory data.
Results
The study found that 64.3% of patients displayed increased AEA levels (>20 ng/mL). A poorer hemoglobin response after two months (ΔHb) was associated with increased AEA levels (β = -15.21, P=0.002). Additionally, a higher erythropoietin resistance index (ERI) emerged as a significant positive predictor (β = 1.50, P=0.018), while lower serum albumin demonstrated a protective effect (β = -22.50, P=0.048).
Conclusion
This study indicates a significant prevalence of AEA in patients with ESRD undergoing EPO therapy. Regression analysis revealed that a poorer hemoglobin response (ΔHb) and a higher ERI were independent predictors of elevated AEA titers, while serum albumin was a protective factor.
Zitieren
APA
Mohammed, S. I., Jamal, M. Y., Nassir, K. F., & Abdulazeez, Z. D. (2025). Association between anti-erythropoietin antibody levels and treatment response in hemodialysis patients with end-stage renal disease: A cross-sectional study from Iraq. Journal of Nephropharmacology, 15(1), e12808. https://doi.org/10.34172/npj.2025.12808
Vancouver
Mohammed SI, Jamal MY, Nassir KF, Abdulazeez ZD. Association between anti-erythropoietin antibody levels and treatment response in hemodialysis patients with end-stage renal disease: A cross-sectional study from Iraq. Journal of Nephropharmacology. 2025;15(1):e12808. doi:10.34172/npj.2025.12808
BibTeX
@article{Mohammed2025,
author = {Mohammed, Samer Imad and Jamal, Mohammed Yawuz and Nassir, Kawthar Faris and Abdulazeez, Zahraa Duraid},
title = {Association between anti-erythropoietin antibody levels and treatment response in hemodialysis patients with end-stage renal disease: A cross-sectional study from Iraq},
journal = {Journal of Nephropharmacology},
year = {2025},
volume = {15},
number = {1},
pages = {e12808},
doi = {10.34172/npj.2025.12808}
}
EUVIMED